Herb Greenberg  |  On the Street

Herb Greenberg | On the Street

Share this post

Herb Greenberg  |  On the Street
Herb Greenberg | On the Street
Red Flag Alert – An Overlooked Risk at DexCom. Also, Updates on Past Red Flag Alerts.
Copy link
Facebook
Email
Notes
More
Red Flag Alerts

Red Flag Alert – An Overlooked Risk at DexCom. Also, Updates on Past Red Flag Alerts.

Herb Greenberg's avatar
Herb Greenberg
Aug 24, 2023
∙ Paid
12

Share this post

Herb Greenberg  |  On the Street
Herb Greenberg | On the Street
Red Flag Alert – An Overlooked Risk at DexCom. Also, Updates on Past Red Flag Alerts.
Copy link
Facebook
Email
Notes
More
6
1
Share

Just because something isn't listed in the 'risk factors' section of a company's regulatory filings doesn't mean it's not a possible 'risk'...

Take DexCom (DXCM), for example. It's a wildly successful manufacturer of continuous glucose monitors ("CGMs"), which just happens to be headquartered not far from me here in San Diego.

Because of the stock's remarkable rise, DexCom has steamrolled its share of skeptics and short sellers over the years, who felt the company was overstating the potential size of its end market... and understating the potential impact from competition.

As it turns out, even with competition – mostly from Abbott Laboratories (ABT) – it has done exceedingly well.

The reason is obvious: With a CGM, you don't have to stick yourself in the finger several times a day to test your blood sugar. You wear it for a week or two – just set it and forget it.

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Herb Greenberg
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More